Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free FBIOP Stock Alerts

Fortress Biotech (FBIOP) News Today

Fortress Biotech logo
$18.30 +0.03 (+0.16%)
As of 08/21/2026 03:33 PM Eastern
Compare

Fortress Biotech Latest News

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344925/28889/en/fortress-biotech-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights.html
Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927931-fortress-biotech-just-netted-159-million-its-preferred-shares-could-be-the-real-winner
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
July 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fortress-biotech-subsidiary-urica-therapeutics-120000778.html
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296616/28889/en/fortress-biotech-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference.html
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295389/28889/en/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights.html
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286702/28889/en/fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference.html
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266013/28889/en/fortress-biotech-reports-2025-financial-results-and-recent-corporate-highlights.html
Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 25, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67766170-fortress-biotech-inc-fortress-biotech-s-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-vouche-399.htm
FBIO shares rally after unit sells priority review voucher for $205 million: Retail now pins hopes on gene therapy
February 23, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/fbio-shares-rally-after-unit-sells-priority-review-voucher-for-205-million-retail-now-pins-hopes-on-gene-therapy/ar-AA1WUAdY
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher
February 23, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/fortress-biotech-to-receive-205m-as-cyprium-agrees-sale-of-rare-pediatric-disease-priority-review-voucher/ar-AA1WUaUu
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/update-fortress-biotech-s-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-205-million-1035855161
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/fortress-biotech-s-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-205-million-1035855020
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/update-fortress-biotech-s-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-205-million.html
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/23/3242632/28889/en/fortress-biotech-s-subsidiary-cyprium-therapeutics-enters-into-agreement-to-sell-rare-pediatric-disease-priority-review-voucher-for-205-million.html
Fortress Biotech (FBIO) Receives a Buy from H.C. Wainwright
January 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/FBIO/pressreleases/37035932/fortress-biotech-fbio-receives-a-buy-from-hc-wainwright/
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
January 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/13/3217693/28889/en/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda-approval-of-zycubo-copper-histidinate-the-first-and-only-approved-treatment-for-menkes-disease-in-the-united-states.html
Fortress Biotech files to sell 600,000 shares of common stock for holders
December 16, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/fortress-biotech-files-to-sell-600000-shares-of-common-stock-for-holders/ar-AA1SsDCa
Fortress Biotech price target raised to $4.50 from $4 at Alliance Global
November 19, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/fortress-biotech-price-target-raised-to-4-50-from-4-at-alliance-global/ar-AA1QKxaG
Fortress Biotech, Inc. (NASDAQ:FBIO) Q3 2025 Earnings Call Transcript
November 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/fortress-biotech-inc-nasdaq-fbio-q3-2025-earnings-call-transcript/ar-AA1QrsWr
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/14/3188314/28889/en/fortress-biotech-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights.html
Fortress Biotech stock rises after subsidiary’s gout treatment enters Phase 3 trials
October 21, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/fortress-biotech-stock-rises-after-subsidiarys-gout-treatment-enters-phase-3-trials-93CH-3930302
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
October 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/fortress-biotech-and-subsidiary-urica-therapeutics-announce-first-patients-dosed-in-crystalys-therapeutics-global-phase-3-trials-of-dotinurad-for-the-treatment-of-gout.html
US FDA declines to approve Fortress Bio and Zydus' treatment for a rare pediatric disease
October 1, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/us-fda-declines-to-approve-fortress-bio-and-zydus-treatment-for-a-rare-pediatric-disease/ar-AA1NFjwv
Why Is Fortress Biotech Stock Falling Today?
October 1, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/why-is-fortress-biotech-stock-falling-today/ar-AA1NFxfm
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
October 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeutics-205-million-series-a-financing-1035242156
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
October 1, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/fortress-biotech-cyprium-therapeutics-announce-120000753.html
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
October 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/01/3159491/28889/en/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeutics-205-million-series-a-financing.html
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
October 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/01/3159486/28889/en/fortress-biotech-and-cyprium-therapeutics-announce-an-update-on-the-nda-for-cutx-101.html
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/02/3142697/28889/en/fortress-biotech-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference.html
Journey Medical’s Q2 2025: Emrosi Gains Traction
August 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/journey-medical-s-q2-2025-emrosi-gains-traction/ar-AA1Kzz5Y
Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 15, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-08/66189361-fortress-biotech-inc-fortress-biotech-reports-second-quarter-2025-financial-results-and-recent-corporate-highlights-399.htm
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/14/3133836/28889/en/fortress-biotech-reports-second-quarter-2025-financial-results-and-recent-corporate-highlights.html
FBIOP | Fortress Biotech Inc. 9.375% Cum. Pfd. Series A Analyst ...
July 11, 2025  |  wsj.comhttps://www.wsj.com/market-data/quotes/FBIOP/research-ratings
Fortress Biotech Inc. 9.375% Cum. Pfd. Series A FBIOP (U.S.: Nasdaq) - The Wall Street Journal
July 5, 2025  |  wsj.comhttps://www.wsj.com/market-data/quotes/FBIOP/company-people/executive-profile/217754269
Fortress Biotech, Inc. (FBIO) Balance Sheet - Yahoo Finance
July 3, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/FBIO/balance-sheet/
Fortress Biotech shareholders approve board proposals at annual meeting
June 24, 2025  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/fortress-biotech-shareholders-approve-board-proposals-at-annual-meeting-93CH-4142170
FBIO - Fortress Biotech Inc Valuation - Morningstar
June 24, 2025  |  morningstar.comM
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
May 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/30/3091157/28889/en/fortress-biotech-announces-closing-of-sale-of-subsidiary-checkpoint-therapeutics.html
Fortress Biotech First Quarter 2025 Earnings: Beats Expectations
May 17, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/fortress-biotech-first-quarter-2025-121411711.html
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 15, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/15/3082650/28889/en/fortress-biotech-reports-first-quarter-2025-financial-results-and-recent-corporate-highlights.html
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/07/3076097/28889/en/fortress-biotech-to-participate-in-the-h-c-wainwright-1st-annual-royalty-company-virtual-conference.html
Fortress Biotech partners with Partex for AI-driven drug discovery
March 19, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/fortress-biotech-partners-with-partex-for-aidriven-drug-discovery-93CH-3982605
Fortress Biotech, Partex enter collaboration for asset identification, evaluatio
March 17, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/fortress-biotech-partex-enter-collaboration-for-asset-identification-evaluatio-1034484045
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
March 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/17/3043727/28889/en/partex-and-fortress-biotech-announce-strategic-collaboration-to-accelerate-asset-identification-and-evaluation-using-proprietary-ai-platform.html
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details
March 10, 2025  |  benzinga.comhttps://www.benzinga.com/25/03/44223752/india-based-sun-pharma-to-buy-us-cancer-firm-checkpoint-therapeutics-for-410-per-share
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
March 10, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/checkpoint-therapeutics-jumps-after-deal-to-be-acquired-by-sun-pharma-1034460203
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
March 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/india-s-sun-pharma-buys-onco-derma-firm-checkpoint-therapeutics-for-355m/ar-AA1AArwV
Triplex vaccine enters Phase 2 trial in stem cell donors
January 27, 2025  |  msn.comhttps://www.msn.com/en-us/science/biology/triplex-vaccine-enters-phase-2-trial-in-stem-cell-donors/ar-AA1xWqXQ
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
January 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/01/27/3015614/28889/en/fortress-biotech-announces-first-patient-dosed-in-phase-2-clinical-trial-of-triplex-vaccination-in-stem-cell-donors-to-reduce-cmv-events-in-recipients-of-hsct.html
Fortress Biotech, Inc. (FBIO) stock forecast and price target
January 18, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/research/stock-forecast/FBIO/

Fortress Biotech Media Mentions By Week

Fortress Biotech Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FBIOP
News Sentiment
▼
0.00

0.65
▲
Average
Healthcare
News Sentiment

Fortress Biotech News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FBIOP Articles
This Week
▼
0

1
▲
FBIOP Articles
Average Week

Fortress Biotech Trends on MarketBeat

This week vs. last week
Page Views
499
-3%
Get Fortress Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBIOP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

This page (NASDAQ:FBIOP) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel